First Indigenous Antibiotic “Nafithromycin” to Combat AMR

In November 2024, Union Minister Dr. Jitendra Singh launched Nafithromycin, India’s first indigenously developed antibiotic aimed at combating Antimicrobial Resistance (AMR).

  • Research & Investment: Developed with support from the Biotechnology Industry Research Assistance Council (BIRAC) under the Department of Biotechnology.
  • Time & Cost: Took 14 years of research and an investment of Rs. 500 crore.
  • Marketed By: Wockhardt, under the trade name “Miqnaf”.

Features and Benefits

  • Designed to Treat: Community-Acquired Bacterial Pneumonia (CABP), a severe illness caused by drug-resistant bacteria.
  • Effectiveness: 10 times more potent than existing treatments like Azithromycin.
  • Treatment Regimen: Requires only a three-day course.
  • Regulatory Approval: Awaiting final clearance from the Central Drugs ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content

Already a Member? Login here

Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material since 2018 of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Be an Annual Subscriber

Current Affairs